These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22541981)

  • 1. Relaxin-2 may offer therapeutic advantages in end-stage heart failure.
    Zhao Z; Liu T; Li G
    Int J Cardiol; 2012 Jun; 157(3):432-3. PubMed ID: 22541981
    [No Abstract]   [Full Text] [Related]  

  • 2. Advancing care for acute heart failure--no time to relax.
    Hernandez AF; Granger CB
    Lancet; 2009 Apr; 373(9673):1401-2. PubMed ID: 19329180
    [No Abstract]   [Full Text] [Related]  

  • 3. Relaxin family peptide receptors--from orphans to therapeutic targets.
    van der Westhuizen ET; Halls ML; Samuel CS; Bathgate RA; Unemori EN; Sutton SW; Summers RJ
    Drug Discov Today; 2008 Aug; 13(15-16):640-51. PubMed ID: 18675759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relaxin, a pleiotropic vasodilator for the treatment of heart failure.
    Teichman SL; Unemori E; Dschietzig T; Conrad K; Voors AA; Teerlink JR; Felker GM; Metra M; Cotter G
    Heart Fail Rev; 2009 Dec; 14(4):321-9. PubMed ID: 19101795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction.
    Murtaza G; Siddiqui A; Hussain I
    Curr Protein Pept Sci; 2018; 19(11):1079-1087. PubMed ID: 29984650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [What is new in the medical management of acute heart failure?].
    Meyer P; White M; Keller RF; Lerch R; Hullin R
    Rev Med Suisse; 2010 Jun; 6(252):1211-7. PubMed ID: 20614757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term vasodilator therapy for chronic congestive heart failure: is it effective?].
    Yasuda H; Obata H
    Kokyu To Junkan; 1985 Mar; 33(3):241-5. PubMed ID: 3892610
    [No Abstract]   [Full Text] [Related]  

  • 8. The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling.
    Dschietzig T; Alexiou K; Kinkel HT; Baumann G; Matschke K; Stangl K
    J Card Fail; 2011 Feb; 17(2):158-66. PubMed ID: 21300306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First clinical experience with intravenous recombinant human relaxin in compensated heart failure.
    Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K
    Ann N Y Acad Sci; 2009 Apr; 1160():387-92. PubMed ID: 19416226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relaxin for treatment of acute heart failure: making the case for treating targeted patient profiles.
    Hernandez-Montfort JA; Arora S; Slawsky MT
    Curr Heart Fail Rep; 2013 Sep; 10(3):198-203. PubMed ID: 23836112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relaxin: a new approach for the treatment of acute congestive heart failure.
    Grossman J; Frishman WH
    Cardiol Rev; 2010; 18(6):305-12. PubMed ID: 20926940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic modulation in heart failure: high time for a definitive clinical trial.
    Ashrafian H; Neubauer S
    Heart; 2011 Feb; 97(4):267-8. PubMed ID: 21258118
    [No Abstract]   [Full Text] [Related]  

  • 13. Relaxin: not a health hazard but a promising therapeutic opportunity.
    Bigazzi M; Bani D; Dschietzig T
    Bone; 2010 Oct; 47(4):832-3; author reply 834. PubMed ID: 20488260
    [No Abstract]   [Full Text] [Related]  

  • 14. Vasodilator therapy for chronic heart failure.
    Mason DT; Awan NA; Demaria AN; Lee G; Joye JA; Amsterdam EA
    Compr Ther; 1979 Jul; 5(7):6-14. PubMed ID: 383392
    [No Abstract]   [Full Text] [Related]  

  • 15. [Vasodilator agents in the treatment of chronic cardiac insufficiency].
    Luis AS
    Acta Med Port; 1979; 1(1):173-5. PubMed ID: 549458
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of chronic heart failure with vasodilator agents].
    Zähringer J; Schultheiss HP
    Internist (Berl); 1986 May; 27(5):315-21. PubMed ID: 3015822
    [No Abstract]   [Full Text] [Related]  

  • 17. [Vasodilator treatment of chronic heart failure].
    Froer KL; Hall D; Goppel L; Rudolph W
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1117-9. PubMed ID: 1029939
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel pharmacologic therapies in development for acute decompensated heart failure.
    Ezekowitz JA
    Curr Cardiol Rep; 2013 Feb; 15(2):329. PubMed ID: 23314727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vasodilator agents in the treatment of acute and chronic cardiac insufficiency].
    Phaneuf DC; Théroux P; Waters DD; Pelletier GB; Mizgala HF
    Union Med Can; 1979 Jul; 108(7):791-5. PubMed ID: 505654
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel vasodilators in heart failure.
    Zamani P; Greenberg BH
    Curr Heart Fail Rep; 2013 Mar; 10(1):1-11. PubMed ID: 23299783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.